Antibodies to rat Thy-1, and also to murine Thy-1, could provoke reverse passive cutaneous anaphylaxis-like (RPCA-like) reactions. The threshold amount of purified anti-Thy-1 antibodies for RPCA-like reactions was 12.5 μg/ml. No RPCA-like reactions were obtained with IgGl F(ab′)2 anti-Thy-1. Cross-linking the murine anti-rat Thy-1 F(ab′)2 fragments with goat antibody against murine F(ab′)2 anti-rat Thy-1 permitted us to obtain RPCA-like reactions with as little as 1.5 μg/ ml. However, when the cross-linking was done with the F(ab′)2 of the same goat antibody, no RPCA-like reactions were obtained. The antibody against rat FcεRIα or its F(ab′)2 product were equally effective in producing RPCA-like reactions; the threshold was obtained with 1.5 μg/ml. The mechanism of the difference is discussed.

Keywords:
Thy-1, Reverse passive cutaneous anaphylaxis, Passive cutaneous anaphylaxis, Mast cell, Rat basophilic leukemia cell, FcεRI
This content is only available via PDF.
© 1997 S. Karger AG, Basel
1997
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.